Insider Transactions in Q2 2024 at Liquidia Corp (LQDA)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2024
|
Katherine Rielly Gauvin Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+50.0%
|
-
|
|
Jun 20
2024
|
Raman Singh Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+50.0%
|
-
|
|
Jun 20
2024
|
Stephen M Bloch Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+50.0%
|
-
|
|
Jun 20
2024
|
Damian De Goa Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+23.02%
|
-
|
|
Jun 20
2024
|
Joanna Horobin Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+50.0%
|
-
|
|
Jun 20
2024
|
David Edward Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+50.0%
|
-
|
|
Jun 20
2024
|
Arthur S Kirsch Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+47.66%
|
-
|
|
Jun 20
2024
|
Paul B Manning Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+6.36%
|
-
|
|
Jun 03
2024
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
546
-0.36%
|
$7,644
$14.55 P/Share
|
|
Jun 03
2024
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
710
-0.15%
|
$9,940
$14.55 P/Share
|
|
Jun 03
2024
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
455
-0.4%
|
$6,370
$14.55 P/Share
|
|
Jun 03
2024
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
1,094
-0.34%
|
$15,316
$14.55 P/Share
|
|
May 31
2024
|
Scott Moomaw Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+1.2%
|
-
|
|
May 31
2024
|
Russell Schundler General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.48%
|
-
|
|
May 31
2024
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,563
+1.37%
|
-
|
|
May 31
2024
|
Michael Kaseta CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.73%
|
-
|
|
Apr 19
2024
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,649
-0.77%
|
$21,437
$13.68 P/Share
|
|
Apr 12
2024
|
Roger Jeffs Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,360
-1.0%
|
$117,040
$14.58 P/Share
|
|
Apr 12
2024
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
3,136
-0.99%
|
$43,904
$14.58 P/Share
|
|
Apr 12
2024
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,585
-1.03%
|
$22,190
$14.58 P/Share
|
|
Apr 12
2024
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,525
-0.71%
|
$21,350
$14.58 P/Share
|
|
Apr 12
2024
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
2,060
-0.42%
|
$28,840
$14.58 P/Share
|
|
Apr 12
2024
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,189
-1.05%
|
$16,646
$14.58 P/Share
|
|
Apr 11
2024
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,906
+3.35%
|
-
|